

REFERENCES

I-85-016

1. Biogen Idec, Inc., Elan Pharmaceuticals, Inc. Tysabri (natalizumab) injection for intravenous use. Highlights of Prescribing Information. Revised 05/2016. [Website]
2. Bright RJ, Wilkinson J, Coventry BJ. Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review. *BMC Neurol.* 2014;14:26.
3. Chataway J, Miller D. Natalizumab therapy for multiple sclerosis. *Neurotherapeutics.* Jan 2013;10(1):19-28.
4. Corboy JR, Halper J, Langer-Gould AM, et al. Position Statement: Availability of Disease Modifying Therapies (DMT) for the Treatment of Relapsing Forms of Multiple Sclerosis. The American Academy of Neurology (AAN) and the National MS Society (NMSS). 2015. Accessed May 2, 2017.
5. Elan Pharmaceuticals, Inc. Tysabri (natalizumab) injection for intravenous use. Prescribing Information. I61061-X. South San Francisco, CA: Elan Pharmaceuticals; 2012.
6. Fernández O. Best practice in the use of natalizumab in multiple sclerosis. *Ther Adv Neurol Disord.* 2013;6(2):69-79.
7. Iaffaldano P, Viterbo RG, Paolicelli D, et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. *PLoS One.* 2012;7(4):e35843.
8. Kane SV, Horst S, Sandborn WJ, et al. Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience. *Inflamm Bowel Dis.* 2012 Mar 14.
9. Korzenik J. Natalizumab for treatment of Crohn's disease in adults. In: UpToDate Online Journal [serial online]. Waltham, MA: *UpToDate*; updated January 6, 2015. [Website]:
10. Lichtenstein, G., Hanauer S., Sandborn W., The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's Disease in Adults. [online publication] January 6, 2009.
11. Natalizumab (Tysabri®) [prescribing information]. Cambridge, MA: Biogen Idec; 05/2015..
12. Natalizumab (Tysabri®). Micromedex® Healthcare Series. [Micromedex® 2.0 Web site]. 01/27/2016.
13. National Multiple Sclerosis Society. Multiple Sclerosis Information for Healthcare Professionals. [Website]:
14. Olek M. Natalizumab for relapsing-remitting multiple sclerosis in adults. In: UpToDate Online Journal [serial online]. Waltham, MA: *UpToDate*; updated October 7, 2016. [Website]:
15. Oliver-Martos B, Orpez-Zafra T, Urbaneja P, Maldonado-Sanchez R, Leyva L, Fernández O. Early development of anti-natalizumab antibodies in MS patients. *J Neurol.* 2013;260(9):2343-7.
16. Perkins M, Ryschewitsch C, Liebner J, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. *PLoS Pathog.* Nov 2012;8(11).
17. Stephenson J, Kern D, Agarwal S, et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. *Health Qual Life Outcomes.* 2012;10:155.

18. Voloshyna N; Havrdová E; Hutchinson M; Nehrych T., et al. Natalizumab improves ambulation in relapsing remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. *European Journal Of Neurology* [Eur J Neurol], ISSN: 1468-1331, 2015 Mar; Vol. 22 (3), pp. 570-7.
19. White, M., Sariyer, I., Gordon, J., et al. Diagnostic Assays for Polyomavirus JC and Progressive Multifocal Leukoencephalopathy. *Rev Med Virol.* 2016 March ; 26(2): 102–114.